| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A339 | SC-005 Featured |
|
|
| A340 | RGX-019 Featured |
|
|
| A341 | Amatuximab Featured | Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium. |
|
| A342 | BMS-986148 Featured |
|
|
| A343 | Anetumab Featured | Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor. |
|
| A344 | NIH patent anti-Mesothelin Featured |
|
|
| A345 | CLN-619 Featured |
|
|
| A346 | U.Washington patent anti-MICB Featured |
|
|
| A347 | Imalumab Featured | Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer. |
|
| A348 | Andecaliximab Featured | Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF). |
|
| A349 | Yeda patent anti-MMP-9 Featured |
|
|
| A350 | Anti-MPL/TPOR/CD110 Antibody (TA136) Featured |
|
|
| A351 | Copenhagen Rigshospitalet patent anti-uPARAP Featured |
|
|
| A352 | Quark patent anti-ENDO 180 Featured |
|
|
| A353 | Narnatumab Featured | Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer. |
|
| A354 | Aveo anti-RON Featured |
|
|
| A355 | Anti-MSPR/RON/CD136 Antibody (H5B14) Featured |
|
|
| A356 | Ensituximab Featured | Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer. |
|
| A357 | Gatipotuzumab Featured | Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC). |
|
| A358 | Clivatuzumab Featured | Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. |
|
| A359 | Oregovomab Featured |
|
|
| A360 | Abagovomab Featured | Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc). |
|
| A361 | Sofituzumab Featured | Sofituzumab (MMUC 1206A) is a humanizedized anti-MUC16 recombinant V-kappa antibody. |
|
| A362 | Forerunner patent anti-Muc 17 Featured |
|
|
| A363 | Argenx patent anti-MuSK Featured |
|
|
| A364 | Alt-100 Featured |
|
|
| A365 | Lifastuzumab Featured | Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity. |
|
| A366 | Upifitamab Featured | Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer. |
|
| A367 | Lorvotuzumab Featured | Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. |
|
| A368 | Enfortumab Featured | Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma. |
|
